Stig has served as President and Chief Executive Officer of Kimia Therapeutics, a spin-off of Carmot Therapeutics, since January 2023. Stig co-founded Carmot Therapeutics and served as CEO from Carmot’s inception in 2008 through Kimia’s formation in January 2023. While starting Kimia, Stig continued as an advisor to Carmot and served on Carmot’s Board of Directors from inception through the acquisition by Roche for up to$3.1 billion in January 2024.

Stig founded Carmot with a vision to transform drug discovery by industrializing Chemotype Evolution and applying the technology to high-impact therapeutic targets. Under Stig’s leadership, Carmot developed a deep pipeline including three clinical-stage novel incretin modulators for the treatment of metabolic diseases and contributed to the discovery of LUMAKRAS in collaboration with Amgen.

Prior to Carmot, Stig was director of biology at Sunesis Pharmaceuticals, where he invented Chemotype Evolution and led drug discovery programs in metabolic disease, auto-immunity, and oncology.

Stig holds an MS in biochemistry and a PhD in molecular and cell biology from the University of Copenhagen, Denmark. He conducted his Ph.D. studies in the laboratory of Dr. Robert Tjian at UC Berkeley, where he went on to become a Novartis Fellow of the Life Sciences Research Foundation, studying mammalian brain development as a post-doctoral fellow.